NuCana (NCNA)
(Delayed Data from NSDQ)
$3.10 USD
-0.05 (-1.59%)
Updated Jul 15, 2024 03:58 PM ET
After-Market: $3.11 +0.01 (0.32%) 7:04 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.10 USD
-0.05 (-1.59%)
Updated Jul 15, 2024 03:58 PM ET
After-Market: $3.11 +0.01 (0.32%) 7:04 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Zacks News
Innate Pharma's Filing for Leukemia Drug Accepted in Europe
by Zacks Equity Research
The EMA accepts Innate's (IPHA) marketing application for Lumoxiti, developed to treat relapsed/refractory hairy cell leukemia in adult patients having received minimum two prior systemic therapies.
New Strong Buy Stocks for December 11th
by Tirthankar Chakraborty
Here are 4 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday
Sorrento Turns Down Two All-Cash Takeover Bids, Stock Jumps
by Zacks Equity Research
Sorrento (SRNE) rejects an all-cash unsolicited acquisition proposal from two unknown biopharmaceutical companies. The stock shoots up.
Achillion's (ACHN) Danicopan Gets EMA's PRIME Tag for PNH
by Zacks Equity Research
Achillion's (ACHN) lead pipeline candidate danicopan receives PRIME status from the EMA as a treatment option for PNH in patients, who are not adequately responding to a C5 inhibitor.
Lilly's Pancreatic Cancer Candidate Fails in Phase III Study
by Zacks Equity Research
Lilly's (LLY) immunotherapy candidate, pegilodecakin, falls short of meeting the primary endpoint of OS benefit in a phase III study investigating its usage in metastatic pancreatic cancer.
Novavax Begins Phase III Study on Influenza Vaccine Candidate
by Zacks Equity Research
Novavax (NVAX) starts a pivotal late-stage study on its pipeline candidate NanoFlu influenza vaccine in senior patients. Shares up.
Seattle Genetics' Enfortumab Vedotin BLA Gets Priority Review
by Zacks Equity Research
The FDA accepts Seattle Genetics (SGEN) and Astellas' BLA for enfortumab vedotin under a priority review to treat advanced/metastatic urothelial cancer. A verdict is pending on Mar 15, 2020.
Amgen's Kyprolis Combo Improves PFS in Multiple Myeloma Study
by Zacks Equity Research
Amgen's (AMGN) phase III study on Kyprolis in combination with dexamethasone and J&J's Darzalex meets the goal of progression-free survival for treating relapsed or refractory multiple myeloma.
FDA Grants Orphan Drug Status to Acceleron's PAH Candidate
by Zacks Equity Research
The FDA assigns an orphan drug status to Acceleron's (XLRN) investigational therapy sotatercept for the treatment of patients with pulmonary arterial hypertension. Shares inch up.
NuCana plc (NCNA) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in NuCana plc (NCNA).
Acorda (ACOR) Down More Than 60% in 3 Months: Here's Why
by Zacks Equity Research
Acorda's (ACOR) lead MS drug Ampyra is hit by generic rivalry in the United States, which is hurting the company's top line. Parkinson's disease drug Inbrija can be an ideal replacement.
Akari's Nomacopan Gets Orphan Drug Tag for Rare Disease
by Zacks Equity Research
The FDA assigns an orphan drug status to Akari's (AKTX) nomacopan for the treatment of hematopoietic stem cell transplantation-associated thrombotic microangiopathy, which is a rare disease.
NuCana Stops Patient Enrollment in Pancreatic Cancer Study
by Zacks Equity Research
NuCana (NCNA) suspends patient enrollment in the phase III study on Acelarin, currently evaluated for treating patients with metastatic pancreatic cancer, who were unfit for combination chemotherapy.
NuCana Initiates Dosing in Phase I Study for Solid Tumors
by Zacks Equity Research
NuCana (NCNA) doses the first patient in a phase I study on NUC-7738, which is being evaluated for the treatment of advanced solid tumors.
NuCana's Biliary Tract Cancer Candidate Gets Orphan Drug Tag
by Zacks Equity Research
The FDA confers an orphan drug designation on NuCana's (NCNA) pipeline candidate, Acelarin, for treating patients with biliary tract cancer
Will NuCana Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in NuCana.
Amarin Down on Lower '19 View, Posts Preliminary '18 Results
by Zacks Equity Research
Amarin (AMRN) reports preliminary results for 2018 and issues guidance for 2019. While the results exceeded estimates, outlook missed the same.
Four Biotech Stocks That Popped More Than 50% in 2018
by Zacks Equity Research
The biotech sector has failed to impress the investors in 2018 which has underperformed the broader S&P 500 market. However, we provide four biotech companies which performed well in this scenario.
NuCana Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
NuCana PLC has been struggling lately, but the selling pressure may be coming to an end soon.